Variants

Researchers in the Republic of Korea have conducted a study of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – that could help to inform further studies investigating the increased virulence of variants of concern and interest. // 4.10.2021

Zoonoosivirologian professori Olli Vapalahti: "Rokotteet näyttävät rajoittavan uusien varianttien syntymistä." // 26.9.2021

Twist Bioscience Corporation (Nasdaq: TWST) today reported that its internally-discovered antibody candidate TB202-3 (CoVIC-094), demonstrated potent binding to diverse SARS-CoV-2 variant mutations, including strains with the E484K, N501Y, D614G, Y453F and K417N mutations in pseudovirus assays, indicating this therapeutic antibody may be effective in treating many strains of COVID-19. // 24.9.2021

A new study examines how SARS-CoV-2 variants confer a competitive advantage on the virus, fueling further transmission and mortality. // 23.9.2021

The study found that the delta and epsilon variants exhibited significantly higher infectivity than alpha, with delta containing approximately six times as much infectious virus for the same amount of RNA. // 22.9.2021

Nature Communications - Quantification of the transmissibility and immune escape properties of SARS-CoV-2 variants is necessary to support pandemic planning. //22.9.2021

This report describes an outbreak with the Delta variant in a federal Texas prison among unvaccinated and vaccinated persons.

A novel protein modeling method assesses changes to the conformation of the SARS-CoV-2 spike protein that have been encountered by mutation. // 19.9.2021

// 16.9.2021

Results of a new study led by the University of Maryland School of Public Health show that people infected with the virus that causes COVID-19 exhale infectious virus in their breath – and those infected with the Alpha variant (the dominant strain circulating at the time this study was conducted) put 43 to 100 times more virus into the air than people infected with the original strains of the virus.// 18.9.2021

Researchers in Japan have warned that the Mu (B.1.621) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – appears to be highly resistant to neutralization by sera from convalescent or vaccinated individuals. // 8.9.2021

ECDC regularly assesses new evidence on variants detected through epidemic intelligence, rules-based genomic variant screening or other scientific sources.

Background The B.1.617.2 COVID-19 variant has contributed to the surge in cases in India and has now been detected across the globe, including a notable increase in cases in the UK. // 24.5.2021

Koronavirus sars-cov-2:n entistä tartuttavampi deltamuunnos on levinnyt jo noin 90 maahan. Deltasta tunnetaan myös ärhäkämpi delta plus -muunnos. IS selvitti, mitä deltasta tiedetään.// 28.6.2021

23.6.2021

Objective To estimate the real world effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed covid-19 symptoms (including the UK variant of concern B.1.1.7), admissions to hospital, and deaths. // 13.6.2021

Koronaviruksen herkästi leviävä deltamuunnos aiheuttaa yhä suurempaa huolta terveysviranomaisille, tutkijoille ja hallituksille. Suomen 12 viikon annosväli rokotuksissa on osoittautunut ongelmaksi deltavariantin torjunnassa.// 8.7.2021

Viraston rokotestrategiasta vastaavan johtajan Marco Cavalerin mukaan suoja pätee kaikkiin EMA:n hyväksymiin rokotteisiin.// 1.7.2021

9.7.2021

Four weeks ago, Israel was celebrating a return to normal life in its battle with COVID-19.// 13.7.2021

Background The newly described SARS-CoV-2 lineage C.37 was recently classified as a variant of interest by the WHO (Lambda variant) based on its high circulation rates in South American countries and the presence of critical mutations in the spike protein. The impact of such mutations in infectivity and immune escape from neutralizing antibodies are entirely unknown. Methods We performed a pseudotyped virus neutralization assay and determined the impact of the Lambda variant on infectivity and immune escape using plasma samples from healthcare workers (HCW) from two centers in Santiago, Chile who received the two-doses scheme of the inactivated virus vaccine CoronaVac. // 1.6.2021

Its mutations help it dodge the immune system. Researchers are scrambling to figure out if it is more dangerous or transmissible than Delta.// 14.7.2021

Rokotustahti on hidastunut viime aikoina. Nyt kun maailmalla leviää herkästi tarttuva deltamuunnos, toisen rokoteannoksen ottaminen on asiantuntijoiden mukaan entistä tärkeämpää.// 20.7.2021

Tähän artikkeliin päivittyy uutisia koronatilanteesta maailmalla ja Suomessa.// 23.7.2021

Technical briefing// 23.7.2021

Koronaviruksen valtamuodoksi on noussut delta-muunnos, joka käyttäytyy edeltäjistään poiketen ja aiheuttaa erilaista tautia.// 28.7.2021

New research cautions that removing restrictions when children and other vulnerable groups are unvaccinated may lead to more infectious variants.// 31.7.2021

We’ve been living in a COVID world for more than 18 months now. At the outset of the pandemic, government agencies and health authorities scrambled to inform people on how to identify symptoms of the virus. But as the virus has evolved, it seems the most common symptoms have changed too. // 1.8.2021

New Epsilon variant found in Pakistan in its fourth wave amid the surge of COVID-19 cases// 2.8.2021